Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cognizant Technology Solutions Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while Cognizant Technology Solutions Corp trades at $42.72 (market cap $20.78B). The key difference: Cognizant Technology Solutions Corp is far larger — about 4.6× ACADIA Pharmaceuticals Inc.'s market cap, and Cognizant Technology Solutions Corp pays a 3% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CTSH | |
|---|---|---|
Market Cap | $4.49B | $20.78B |
Sector | Health | Technology |
52-Week High | $28.06 | $86.70 |
52-Week Low | $20.06 | $38.73 |
Enterprise Value | $3.69B | $20.36B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Cognizant Technology Solutions (CTSH) trades at $43.94, up 4.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.97 and net margin of 10.41%, supported by $21.11B revenue in 2025. Recent news highlights AI partnerships with Google Cloud and OpenAI, positioning CTSH for growth in enterprise AI solutions.
Outlook remains positive with a consensus price target of $67.58, implying 54% upside, though near-term risks include soft IT demand and margin pressures. Institutional sentiment is mixed with 43% buy ratings, but the valuation discount and AI expansion present a compelling opportunity for long-term investors amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
